This article has been updated to include comments from the company's analyst conference call.

NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Tuesday that its fourth quarter revenues rose 144 percent, due to a 114 percent uptick year over year in the number of Cologuard colon cancer tests it completed during the quarter.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.